Lipodystrophy (changes in body shape and metabolism) is a side-effect of some older anti-HIV drugs which are now rarely used. The body fat changes include fat gain and fat loss.

Lipodystrophy: latest news

Lipodystrophy resources

  • Side effects

    The most common side effects are the result of your body getting used to a new drug. After a few weeks, these side effects usually...

    From: The basics

    Information level Level 1
  • Lipodystrophy

    Lipodystrophy is a side-effect of some anti-HIV drugs. These are mainly older drugs which are now rarely used. Lipodystrophy may include an accumulation of fat, a loss of...

    From: Factsheets

    Information level Level 2
  • Longer-term side-effects

    Effective HIV treatment has significantly reduced the risk of serious kidney disease in people with HIV. However, most anti-HIV drugs can cause some damage to the kidneys,...

    From: Booklets

    Information level Level 2
  • Conditions related to HIV treatment, metabolic changes and ageing

    Lipodystrophy is a condition which causes changes in body shape and involves fat loss or fat gain in certain parts of the body. Long-term use of some older anti-HIV...

    From: Booklets

    Information level Level 2
  • Lipodystrophy

    This section begins with an overview of metabolic and body-fat changes, including sections on Metabolism - the basics, HIV, HAART and metabolic changes and Treating...

    From: HIV treatments directory

    Information level Level 4

Lipodystrophy features

Lipodystrophy news from aidsmap

More news

Lipodystrophy news selected from other sources

  • Two Experts Discuss HIV, Abdominal Fat and Body Shape Changes

    Watch's HIV and Aging Expert Nelson Vergel interview Dr. Stephen Grinspoon, Professor at Harvard Medical School and the Director of a Program in Nutritional Metabolism at Massachusetts General Hospital about the causes of body shape changes in HIV -- and most importantly, what you can do about them.

    24 August 2016 | The Body
  • Body fat changes and lactic acidosis with HIV medicines: EMA recommends removal of class warnings for several medicines

    The European Medicines Agency (EMA) has updated the advice on the risk of body fat changes and lactic acidosis with medicines for the treatment of human immunodeficiency virus (HIV) infection. As a result, HIV medicines will no longer require a warning concerning fat redistribution in their product information, and a number of medicines of the class ‘nucleoside and nucleotide analogues’ will no longer require a warning about lactic acidosis.

    26 October 2015 | European Medicines Agency
  • Abdominal Body Fat Gains on ART and Viral Load: It Matters Where You Start

    New findings show that people with higher viral loads when starting ART for the first time are more likely to undergo substantial body composition changes, such as an increased amount of fat in the abdominal area (called “central adiposity”), than those who start treatment with a lower viral load (abstract 140).

    04 March 2015 | BETA blog
  • Drug that reduces abdominal fat in HIV patients also may reduce fat in liver

    The only drug to receive Food and Drug Administration approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients. Massachusetts General Hospital investigators report that six months of daily injections of tesamorelin significantly reduced fat in the liver without affecting glucose metabolism.

    19 July 2014 | Eurekalert Medicine & Health
  • Unusual and rare complication described in San Francisco

    Doctors in San Francisco have reported an unusual and rare finding—an apparently harmless but disfiguring condition called cutis verticis gyrata (CVG) on the heads of four HIV-positive men. In CVG, the skin on the head becomes raised in parts and depressed in others, forming ridges and furrows.

    09 December 2013 | CATIE
  • Liquid Injectable Silicone Effective, Safe for Treating HIV Patients with Facial Lipoatrophy

    Research in British Columbia, Canada, indicates that liquid injectable silicone administered properly has potential as a safe, effective, natural feeling treatment for patients with HIV-associated facial lipoatrophy (FLA). The researchers tested liquid injectable silicone because temporary filler treatments were not permanent and could result in high costs.

    04 June 2013 | Healio
  • Protein Structure Discovery Could Lead to Better Treatments for HIV, Early Aging

    Researchers at the University of Virginia School of Medicine have determined the molecular structure of a protein whose mutations have been linked to several early aging diseases, and to side effects of common HIV and AIDS medications.

    11 April 2013 | University of Virginia press release
  • Health Canada rejects tesamorelin for lipodystrophy

    After consideration of the NDS, Health Canada decided that the risks of tesamorelin outweighed its benefits under the proposed conditions of use.

    13 March 2013 | Theratechnologies press release
  • Mark S. King: I'm Gonna Wipe That AIDS Right Off My Face

    It was all well and good to be front and center as an HIV-positive man during the first years of the AIDS crisis. It's easier being a role model when your face looks good on the poster. But then, slowly but surely, a common side effect of HIV medications, facial wasting, began to appear.

    30 January 2013 | Huffington Post
  • The Bio-Alcamid disaster

    “Nightmare.” That’s how one man described a weeks-long ordeal involving ad hoc surgery, repeated infections and some hefty out-of-pocket fees – all caused by a device that was once thought to be a miracle for those dealing with the visible signs of HIV.

    08 October 2012 | Xtra
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.